Ophthalmology Advisor’s Post

🎥 Delve into the science of dosing with Dr. Peter Kaiser as he discusses the enhanced durability of Bayer | Ophthalmology 8 mg aflibercept. Learn how increasing the molar dose can extend the drug's half-life, offering tailored treatment intervals based on individual patient needs. Dr. Kaiser sheds light on the practical application of these findings, emphasizing the importance of a patient-centric approach in optimizing treatment outcomes. Explore the nuances of treat-and-extend paradigms with high-dose Eylea, and discover how personalized care is revolutionizing patient experiences in ophthalmology.  #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress Simrat Sodhi

Most viewed in the last 7 days from JAMA Ophthalmology: In-office suprachoroidal viscopexy (SCVEXY) for primary acute rhegmatogenous retinal detachment showed promising results, with 5 out of 6 patients achieving successful reattachment without additional procedures. https://ja.ma/3ZO6HJj

🎥 Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress

An assessment of patients with Central Retinal Artery Occlusion published in the American Journal of Ophthalmology ! - Most present within 24 hours of symptoms and with elevated inflammatory makers - Visual recovery and reperfusion are possible, both with and without the presence of a cilioretinal artery - Total and inner retinal thickening was observed on OCT at presentation, with subsequent progressive retinal thinning stabilizing after 6 months. - This modern data set can serve as a comprehensive baseline analysis for future interventional trials Great work by Sandra Hoyek and thanks to the mentorship of Demetrios Vavvas on the project! https://lnkd.in/esB_-Ub3

There will be intra ocular injection If 1 mm is used in a area of thin sclera I think this is a good option for inferior pathology not reachable this a gas bubble PnR superior 2/3 SCVEXY inferior 1/3

We need more efficacy and safety data. However, the potential of a treatment that involves no incisions, no gas/tamponade and no positioning provides an opportunity to transform care for patients with retinal detachment. For the past decade we have been trying to find ways to optimize visual function by improving the “integrity” of reattachment with less photoreceptor disruption, less retinal displacement and less outer retinal folds, all abnormalities that are more common with vitrectomy and associated with worse visual function. Scleral buckle and pneumatic retinopexy have advantages from this perspective but have their own drawbacks such as a more invasive procedure or significant positioning/compliance requirements that restrict a patient’s normal activities. Suprachoroidal Viscopexy (SCVEXY) evolved from this work. Here we have a potential treatment that may not only provide a better “integrity” of reattachment but may also offer unparalleled advantages for patient quality of life with immediate return to normal activities. Although there is much work still to be done, we are excited about what the future may hold for patients with rhegmatogenous retinal detachment and are committed to seeing it through. See article below and associated Invited Commentary in Jama Ophthalmology.

Most viewed in the last 7 days from JAMA Ophthalmology: In-office suprachoroidal viscopexy (SCVEXY) for primary acute rhegmatogenous retinal detachment showed promising results, with 5 out of 6 patients achieving successful reattachment without additional procedures. https://ja.ma/3P4gQNh

A study investigated the impact of latanoprostene bunod on #IOP in patients with #glaucoma and ocular hypertension. Constance Okeke, MD, MSCE, presented the results to Healio. 🔗 👇 #OcularSurgeryNews #Ophthalmology #AAO2024 American Academy of Ophthalmology https://lnkd.in/eWXSjeeB

🔬💡 Dr. David Eichenbaum discusses the significant benchmarks in visual acuity improvements that could change treatment approaches for wet macular degeneration. He emphasizes that an improvement of five or six letters could lead to a straightforward adoption of new treatments, providing a clear benefit to patients. The key is achieving a balance where the benefits justify additional treatments. Tune in as we explore how these clinical outcomes could potentially set new standards in ophthalmology. #ClinicalTrials #Ophthalmology #PatientCare RIWC24: Retina International World Congress 2024

Transitioning from intravitreal aflibercept (IVI AFL) to biosimilar ranibizumab (B-RBZ) can be effective, saving money for patients with diabetic macular edema (DME), research published in Clinical Ophthalmology (Dove Medical Press) suggests. Read here: https://bit.ly/49LjH7g #IntravitrealAflibercept #IVIAFL #BiosimiliarRanibizumab #BRBZ #DiabeticMacularEdema #DME #Ophthalmology #EyeHealth #EyeCare